Bernardsville, NJ, United States of America

Duane A Burnett

This inventor holds 63 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent and 18 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D). Top assignees: Schering Corporation, Merck Sharp + Dohme Corp., Axovant Sciences Gmbh. Active years: 1997-2023.

USPTO Granted Patents = 63 (Patent Applications = 12)

% Patents Active = 60.3

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 18 (Patent Applications = 26)

Average Co-Inventor Count = 4.0

ph-index = 11

Forward Citations = 618(Granted Patents)

Forward Citations (Not Self Cited) = 500(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Fanwood, NJ (US) (1997 - 1998)
Bernardsville, NJ (US) (2003 - 2016)
Wayland, MA (US) (2015 - 2023)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

3 out of 8

Axovant Sciences Gmbh

patents

4. 2 out of 57

Denali Therapeutics Inc.

patents

5. 2 out of 28

Schering-Plough Corporation

patents

6. 1 out of 2

Aquinnah Pharmaceuticals, Inc.

8. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2023

Loading Chart...

Areas of Expertise:

BACE Inhibitors

Gamma Secretase Inhibitors

mGluR1 Antagonists

Aminobenzisoxazole Compounds

Azetidinone Derivatives

Dipeptidyl Peptidase-IV Inhibitors

Thiazine Dioxides

Hypocholesterolemic Agents

Quinuclidine Amides

HCV NS3 Protease Inhibitors

Substituted Azetidinone Compounds

Therapeutic Agents

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11542233 - Compounds, compositions and methods of use (2023-01-03),

2. 10428062 - Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors (2019-10-01),

3. 10370370 - Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors (2019-08-06),

4. 10183938 - Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors (2019-01-22),

5. 9802927 - Oxadiazine compounds and methods of use thereof (2017-10-31),

6. 9771378 - Fused morpholinopyrimidines and methods of use thereof (2017-09-26),

7. 9499502 - 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use (2016-11-22),

8. 9453034 - C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use (2016-09-27),

9. 9365589 - C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use (2016-06-14),

10. 9226927 - Gamma secretase inhibitors (2016-01-05),

11. 9181236 - 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use (2015-11-10),

12. 8987195 - HCV NS3 protease inhibitors (2015-03-24),

13. 8933116 - Gamma secretase inhibitors (2015-01-13),

14. 8907086 - Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors (2014-12-09),

15. 8809318 - Gamma secretase modulators (2014-08-19),

Title: Unveiling the Innovative Journey of Duane A. Burnett

Introduction:

Duane A. Burnett, a prolific inventor hailing from Bernardsville, NJ (US), has left an indelible mark in the field of cognitive enhancement through his groundbreaking inventions. With an impressive portfolio of 62 patents to his name, Burnett's contributions have significantly impacted the realm of pharmaceuticals and cognitive research.

Latest Patents:

In his latest patents, Duane A. Burnett introduces novel geminal substituted aminobenzisoxazole compounds that act as agonists of α7-nicotinic acetylcholine receptors. These compounds, along with pharmaceutical compositions developed from them, hold immense promise in maintaining, treating, and enhancing cognitive function. By administering these compounds to patients with cognitive deficiencies, Burnett's inventions offer new avenues for improving brain health and cognitive abilities.

Career Highlights:

Throughout his illustrious career, Duane A. Burnett has lent his expertise to esteemed companies such as Schering Corporation and Merck Sharp & Dohme Corporation. His innovative spirit and dedication to advancing pharmaceutical research have propelled him to the forefront of the industry, where his patents continue to shape the landscape of cognitive enhancement.

Collaborations:

In his professional endeavors, Duane A. Burnett has collaborated with respected individuals in the field, including Wen-Lian Wu and John W. Clader. Together, they have synergized their knowledge and skills to drive forward cutting-edge research and development initiatives, further cementing Burnett's legacy as a trailblazer in cognitive science.

Conclusion:

In conclusion, Duane A. Burnett's relentless pursuit of innovation and his pioneering work in developing cognitive-enhancing compounds underscore his status as a visionary inventor. His patents not only showcase his scientific acumen but also reflect his unwavering commitment to improving the lives of individuals through advancements in cognitive health. As Burnett continues to push the boundaries of pharmaceutical research, his impact on the field is sure to endure for generations to come.